Microbot Medical Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
The Company has elected not to provide summary information.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MICROBOT MEDICAL INC.
/s/ Harel Gadot
Harel Gadot
President, Chief Executive Officer and Chairman
Dated: March 25, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Harel Gadot | Chairman, President and Chief Executive Officer | March 25, 2025 |
| Harel Gadot | (Principal Executive Officer) | |
| /s/ Rachel Vaknin | Chief Financial Officer | March 25, 2025 |
| Rachel Vaknin | (Principal Financial and Accounting Officer) | |
| /s/ David J. Wilson | Director | March 25, 2025 |
| David J. Wilson | ||
| /s/ Prattipati Laxminarain | Director | March 25, 2025 |
| Prattipati Laxminarain | ||
| /s/ Scott Burell | Director | March 25, 2025 |
| Scott Burell | ||
| /s/ Martin Madden | Director | March 25, 2025 |
| Martin Madden | ||
| /s/ Aileen Stockburger | Director | March 25, 2025 |
| Aileen Stockburger | ||
| /s/ Tal Wenderow | Director | March 25, 2025 |
| Tal Wenderow | ||
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 1197) | F-2 – F-3 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024, and 2023 | F-4 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| Notes to the Consolidated Financial Statements | F-8 – F-32 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.